IMRT Course 2016

TROG 96.01: 10-year all-cause

mortality

6-month ADT + RT

vs RT alone:

p=0.0008

3- and 6-month ADT significantly

reduced PSA progression, local

progression and improved event-

free survival

Denham JW, et al. Lancet Oncol 2011;12:451-9

Frommultivariate model with covariates of treatment group, age, Gleason score, initial PSA and prostate cancer stage

NADT, neoadjuvant androgen deprivation therapy

PSA, prostate-specific antigen; RT, radiotherapy

6-month ADT also significantly

improved distant progression and

prostate cancer mortality